Clinical Trials Browser

Phase 1/2 × Carcinoma, Renal Cell × tislelizumab × Clear all

NCT05661955 2025-11-21

A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.

Phase 1/2 Active not recruiting

DermatologicGenitourinary

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma